Effects of sTAT3 gene silencing and rapamycin on apoptosis in hepatocarcinoma cells

International Journal of Medical Sciences

Volumn 9, Issue 3, 2012, Pages 216-224

  Zhang, Yi ^a   Zhang, Jun Wei ^b   Lv, Guo Yue ^a   Xie, Shu Li ^a   Wang, Guang Yi ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b JINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Hepatocelluar carcinoma; mTOR; Rapamycin; RNAi; STAT3

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; CASPASE 3; LIPOCORTIN 5; MAMMALIAN TARGET OF RAPAMYCIN; PLASMID VECTOR; PROPIDIUM IODIDE; RAPAMYCIN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL MEMBRANE DEPOLARIZATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; EXPRESSION VECTOR; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; LIVER CELL CARCINOMA; MITOCHONDRIAL MEMBRANE; ONCOGENE; STAINING; STAT3 GENE; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE SILENCING; HUMANS; LIVER NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; RNA INTERFERENCE; SIROLIMUS; STAT3 TRANSCRIPTION FACTOR; TOR SERINE-THREONINE KINASES;

EID: 84863273482     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.4004     Document Type: Article

References (26)

1. EI-Serag HB, Rudolph KL. Hepatocellular carcinom: epidemi-ology and molecular cacinogenesis. Gastroenterology. 2007;132:2557-2576.
2. Llovet JM. Updated treatment approach to hepatocellular car-cinoma. J Gastroenterol. 2005;40:225-235.
3. Ando E, Tanaka M, Yamashita F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002;95:588-595.
4. Beerenwinkel N, Antal T, Dingli D, et al. Genetic progression and the waiting time to cancer. PLoS Comput Biol. 2007;3:e225.
5. Boland CR, Goel A. Somatic evolution of cancer cells. Semin Cancer Biol. 2005;15:436-450.
6. Bild AH, Potti A, Nevins JR. Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer. 2006;6:735-741.
7. Dworakowska D, Wlodek E, Leontiou CA, et al. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer. 2009;16:1329-1338.
8. Hui IC, Tung EK, Sze KM, et al. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma. Liver Int. 2010;30:65-75.
9. Treiber G. mTOR inhibitors for hepatocellular cancer: a for-ward-moving target. Expert Rev Anticancer Ther. 2009;9:247-261.
10. Cheng G, Lin J. Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun. 2005;335:292-299.
11. Seita J, Asakawa M, Ooehara J, et al. Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood. 2008;111:1903-1912.
12. Li WC, Ye SL, Sun RX, et al. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleo-tide targeting signal transducer and activator of transcription3. Clin Cancer Res. 2006;12:7140-7148.
13. Kiyotaka Yokogami, Shinichiro Wakisaka, Joseph Avruch, et al. Serine phosphorylation and maximal activation of STAT3 dur-ing CNTF signaling is mediated by the rapamycin target mTOR. Current Biology. 2000;10:47-50.
14. Rosner M, Hanneder M, Siegel N, et al. The mTOR pathway and its role in human genetic diseases. Mutat Res. 2008;659:284-292.
15. Mansure JJ, Nassim R, Chevalier S, et al. Inhibition of mamma-lian target of rapamycin as a therapeutic strategy in the man-agement of bladder cancer. Cancer Biol Ther. 2009;8: 2339-2347.
16. Sato T, Nakashima A, Tamanoi F. Rheb-mTOR signaling pathway involved in tumor formation. Tanpakushitsu Kakusan Koso. 2010;55:11-17.
17. Shailly Varma, Ramji L. Khandelwal. Effects of rapamycin on cell proliferation and phosphorylation of mTOR and p70S6K in HepG2 and HepG2 cells overexpressing constitutively active Akt/PKB. Biochimica et Biophysica Acta. 2007;1770:71-78.
18. Hudes GR. Targeting mTOR in renal cell carcinoma. Cancer. 2009;115:2313-2320.
19. Petroulakis E, Mamane Y, Le Bacquer O, et al. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer. 2007;96:R11-15.
20. Niu G, Bowman T, Huang M, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene. 2002;21:7001-7110.
21. Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 2008;18:254-267.
22. Fellmann C, Zuber J, McJunkin K, et al. Functional Identification of Optimized RNAi Triggers Using a Massively Parallel Sensor Assay. Molecular Cell. 2011;41:733-746
23. M. Okamoto, C. Lee, R. Oyas. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res. 1997;57:141-146
24. Yam JW, Wong CM, Ng IO. Molecular and functional genetics of hepatocellular carcinoma. Front Biosci (Schol Ed). 2010;2:117-134.
25. Bromberg J, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell. 2009;15:79-80.
26. Farnebo M, Bykov VJ, Wiman KG. The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun. 2010; 396:85-89.